+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Migraine Drugs Market Research Report by Therapeutic Class, Treatment Type, Route of Administration, Distribution, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 132 Pages
  • July 2022
  • Region: United States
  • 360iResearch™
  • ID: 5123353
UP TO OFF until Dec 31st 2022
The United States Migraine Drugs Market size was estimated at USD 721.50 million in 2021, USD 876.60 million in 2022, and is projected to grow at a CAGR 17.69% to reach USD 1,917.38 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Migraine Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Therapeutic Class, the market was studied across Anti-Nausea Drug, Blood Pressure Lowering Medication, Ergots, Opioid Medication, Pain Reliever, and Triptans. The Anti-Nausea Drug is further studied across Chlorpromazine, Metoclopramide, and Prochlorperazine. The Blood Pressure Lowering Medication is further studied across Beta-Blocker and Calcium Channel Blocker. The Ergots is further studied across Dihydroergotamines, Ergotamine, and Lasmiditan. The Opioid Medication is further studied across OxyContin, Percocet, and Vicodin. The Pain Reliever is further studied across Aspirin and Ibuprofen. The Triptans is further studied across Rizatriptan and Sumatriptan.
  • Based on Treatment Type, the market was studied across Abortive and Preventive.
  • Based on Route of Administration, the market was studied across Injectable, Nasal Spray, and Oral.
  • Based on Distribution, the market was studied across Hospitals Based Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Migraine Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Migraine Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Migraine Drugs Market, including Aegis Therapeutics, Alder Biopharmaceuticals, Allergan, Eli Lilly, GlaxoSmithKline, Impax Laboratories, Johnson & Johnson, Luitpold Pharmaceuticals, Pfizer, TG Therapeutics, and Winston Pharmaceuticals.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Migraine Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Migraine Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Migraine Drugs Market?
4. What is the competitive strategic window for opportunities in the United States Migraine Drugs Market?
5. What are the technology trends and regulatory frameworks in the United States Migraine Drugs Market?
6. What is the market share of the leading vendors in the United States Migraine Drugs Market?
7. What modes and strategic moves are considered suitable for entering the United States Migraine Drugs Market?
Frequently Asked Questions about the U.S. Migraine Drugs Market

What is the estimated value of the U.S. Migraine Drugs Market?

The U.S. Migraine Drugs Market was estimated to be valued at $721.5 Million in 2021.

What is the growth rate of the U.S. Migraine Drugs Market?

The growth rate of the U.S. Migraine Drugs Market is 17.6%, with an estimated value of $1917.38 Million by 2027.

What is the forecasted size of the U.S. Migraine Drugs Market?

The U.S. Migraine Drugs Market is estimated to be worth $1917.38 Million by 2027.

Who are the key companies in the U.S. Migraine Drugs Market?

Key companies in the U.S. Migraine Drugs Market include Aegis Therapeutics, Alder Biopharmaceuticals, Allergan, Eli Lilly, GlaxoSmithKline, Impax Laboratories, Johnson & Johnson, Luitpold Pharmaceuticals and TG Therapeutics.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Migraine Drugs Market, by Therapeutic Class
6.1. Introduction
6.2. Anti-Nausea Drug
6.2.1. Chlorpromazine
6.2.2. Metoclopramide
6.2.3. Prochlorperazine
6.3. Blood Pressure Lowering Medication
6.3.1. Beta-Blocker
6.3.2. Calcium Channel Blocker
6.4. Ergots
6.4.1. Dihydroergotamines
6.4.2. Ergotamine
6.4.3. Lasmiditan
6.5. Opioid Medication
6.5.1. Oxycontin
6.5.2. Percocet
6.5.3. Vicodin
6.6. Pain Reliever
6.6.1. Aspirin
6.6.2. Ibuprofen
6.7. Triptans
6.7.1. Rizatriptan
6.7.2. Sumatriptan
7. Migraine Drugs Market, by Treatment Type
7.1. Introduction
7.2. Abortive
7.3. Preventive
8. Migraine Drugs Market, by Route of Administration
8.1. Introduction
8.2. Injectable
8.3. Nasal Spray
8.4. Oral
9. Migraine Drugs Market, by Distribution
9.1. Introduction
9.2. Hospitals Based Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. California Migraine Drugs Market11. Florida Migraine Drugs Market12. Illinois Migraine Drugs Market13. New York Migraine Drugs Market14. Ohio Migraine Drugs Market15. Pennsylvania Migraine Drugs Market16. Texas Migraine Drugs Market
17. Competitive Landscape
17.1. Fpnv Positioning Matrix
17.1.1. Quadrants
17.1.2. Business Strategy
17.1.3. Product Satisfaction
17.2. Market Ranking Analysis
17.3. Market Share Analysis, by Key Player
17.4. Competitive Scenario
17.4.1. Merger & Acquisition
17.4.2. Agreement, Collaboration, & Partnership
17.4.3. New Product Launch & Enhancement
17.4.4. Investment & Funding
17.4.5. Award, Recognition, & Expansion
18. Company Usability Profiles
18.1. Aegis Therapeutics
18.2. Alder Biopharmaceuticals
18.3. Allergan
18.4. Eli Lilly
18.5. GlaxoSmithKline
18.6. Impax Laboratories
18.7. Johnson & Johnson
18.8. Luitpold Pharmaceuticals
18.9. Pfizer
18.10. Tg Therapeutics
18.11. Winston Pharmaceuticals
19. Appendix
19.1. Discussion Guide
19.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES MIGRAINE DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES MIGRAINE DRUGS MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. UNITED STATES MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2027
FIGURE 7. UNITED STATES MIGRAINE DRUGS MARKET DYNAMICS
FIGURE 8. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2027
FIGURE 11. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2019-2027 (USD MILLION)
FIGURE 12. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 13. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY CHLORPROMAZINE, 2019-2027 (USD MILLION)
FIGURE 14. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 15. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY METOCLOPRAMIDE, 2019-2027 (USD MILLION)
FIGURE 16. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PROCHLORPERAZINE, 2019-2027 (USD MILLION)
FIGURE 18. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PROCHLORPERAZINE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 19. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2019-2027 (USD MILLION)
FIGURE 20. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 21. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY BETA-BLOCKER, 2019-2027 (USD MILLION)
FIGURE 22. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY BETA-BLOCKER, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 23. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, 2019-2027 (USD MILLION)
FIGURE 24. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 25. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2019-2027 (USD MILLION)
FIGURE 26. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 27. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINES, 2019-2027 (USD MILLION)
FIGURE 28. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 29. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, 2019-2027 (USD MILLION)
FIGURE 30. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 31. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, 2019-2027 (USD MILLION)
FIGURE 32. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 33. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2019-2027 (USD MILLION)
FIGURE 34. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 35. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY OXYCONTIN, 2019-2027 (USD MILLION)
FIGURE 36. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY OXYCONTIN, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 37. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PERCOCET, 2019-2027 (USD MILLION)
FIGURE 38. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PERCOCET, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 39. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY VICODIN, 2019-2027 (USD MILLION)
FIGURE 40. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY VICODIN, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 41. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2019-2027 (USD MILLION)
FIGURE 42. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 43. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ASPIRIN, 2019-2027 (USD MILLION)
FIGURE 44. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ASPIRIN, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 45. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, 2019-2027 (USD MILLION)
FIGURE 46. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 47. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2019-2027 (USD MILLION)
FIGURE 48. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 49. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, 2019-2027 (USD MILLION)
FIGURE 50. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 51. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, 2019-2027 (USD MILLION)
FIGURE 52. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 53. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2021 VS 2027 (%)
FIGURE 54. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 55. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2027
FIGURE 56. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ABORTIVE, 2019-2027 (USD MILLION)
FIGURE 57. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ABORTIVE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 58. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE, 2019-2027 (USD MILLION)
FIGURE 59. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 60. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2021 VS 2027 (%)
FIGURE 61. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2021 VS 2027 (USD MILLION)
FIGURE 62. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2027
FIGURE 63. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2019-2027 (USD MILLION)
FIGURE 64. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 65. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY NASAL SPRAY, 2019-2027 (USD MILLION)
FIGURE 66. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY NASAL SPRAY, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 67. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2019-2027 (USD MILLION)
FIGURE 68. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 69. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2021 VS 2027 (%)
FIGURE 70. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2021 VS 2027 (USD MILLION)
FIGURE 71. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2027
FIGURE 72. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS BASED PHARMACY, 2019-2027 (USD MILLION)
FIGURE 73. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS BASED PHARMACY, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 74. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2019-2027 (USD MILLION)
FIGURE 75. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 76. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2019-2027 (USD MILLION)
FIGURE 77. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 78. CALIFORNIA MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 79. FLORIDA MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 80. ILLINOIS MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 81. NEW YORK MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 82. OHIO MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 83. PENNSYLVANIA MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 84. TEXAS MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 85. UNITED STATES MIGRAINE DRUGS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 86. UNITED STATES MIGRAINE DRUGS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 87. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES MIGRAINE DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES MIGRAINE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 5. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY STATE, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PROCHLORPERAZINE, BY STATE, 2019-2027 (USD MILLION)
TABLE 10. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, BY STATE, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY BETA-BLOCKER, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY STATE, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINES, BY STATE, 2019-2027 (USD MILLION)
TABLE 15. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY STATE, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY STATE, 2019-2027 (USD MILLION)
TABLE 17. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, BY STATE, 2019-2027 (USD MILLION)
TABLE 18. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY OXYCONTIN, BY STATE, 2019-2027 (USD MILLION)
TABLE 19. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PERCOCET, BY STATE, 2019-2027 (USD MILLION)
TABLE 20. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY VICODIN, BY STATE, 2019-2027 (USD MILLION)
TABLE 21. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, BY STATE, 2019-2027 (USD MILLION)
TABLE 22. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ASPIRIN, BY STATE, 2019-2027 (USD MILLION)
TABLE 23. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY STATE, 2019-2027 (USD MILLION)
TABLE 24. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY STATE, 2019-2027 (USD MILLION)
TABLE 25. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY STATE, 2019-2027 (USD MILLION)
TABLE 26. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY STATE, 2019-2027 (USD MILLION)
TABLE 27. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2019-2027 (USD MILLION)
TABLE 28. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ABORTIVE, BY STATE, 2019-2027 (USD MILLION)
TABLE 29. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE, BY STATE, 2019-2027 (USD MILLION)
TABLE 30. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
TABLE 31. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY STATE, 2019-2027 (USD MILLION)
TABLE 32. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY NASAL SPRAY, BY STATE, 2019-2027 (USD MILLION)
TABLE 33. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY STATE, 2019-2027 (USD MILLION)
TABLE 34. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 35. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS BASED PHARMACY, BY STATE, 2019-2027 (USD MILLION)
TABLE 36. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY STATE, 2019-2027 (USD MILLION)
TABLE 37. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY STATE, 2019-2027 (USD MILLION)
TABLE 38. CALIFORNIA MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 39. CALIFORNIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2019-2027 (USD MILLION)
TABLE 40. CALIFORNIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2019-2027 (USD MILLION)
TABLE 41. CALIFORNIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
TABLE 42. CALIFORNIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 43. FLORIDA MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 44. FLORIDA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2019-2027 (USD MILLION)
TABLE 45. FLORIDA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2019-2027 (USD MILLION)
TABLE 46. FLORIDA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
TABLE 47. FLORIDA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 48. ILLINOIS MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 49. ILLINOIS MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2019-2027 (USD MILLION)
TABLE 50. ILLINOIS MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2019-2027 (USD MILLION)
TABLE 51. ILLINOIS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
TABLE 52. ILLINOIS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 53. NEW YORK MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 54. NEW YORK MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2019-2027 (USD MILLION)
TABLE 55. NEW YORK MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2019-2027 (USD MILLION)
TABLE 56. NEW YORK MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
TABLE 57. NEW YORK MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 58. OHIO MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 59. OHIO MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2019-2027 (USD MILLION)
TABLE 60. OHIO MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2019-2027 (USD MILLION)
TABLE 61. OHIO MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
TABLE 62. OHIO MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 63. PENNSYLVANIA MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 64. PENNSYLVANIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2019-2027 (USD MILLION)
TABLE 65. PENNSYLVANIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2019-2027 (USD MILLION)
TABLE 66. PENNSYLVANIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
TABLE 67. PENNSYLVANIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 68. TEXAS MIGRAINE DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 69. TEXAS MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2019-2027 (USD MILLION)
TABLE 70. TEXAS MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2019-2027 (USD MILLION)
TABLE 71. TEXAS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
TABLE 72. TEXAS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 73. UNITED STATES MIGRAINE DRUGS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 74. UNITED STATES MIGRAINE DRUGS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 75. UNITED STATES MIGRAINE DRUGS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 76. UNITED STATES MIGRAINE DRUGS MARKET RANKING
TABLE 77. UNITED STATES MIGRAINE DRUGS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 78. UNITED STATES MIGRAINE DRUGS MARKET MERGER & ACQUISITION
TABLE 79. UNITED STATES MIGRAINE DRUGS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 80. UNITED STATES MIGRAINE DRUGS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 81. UNITED STATES MIGRAINE DRUGS MARKET INVESTMENT & FUNDING
TABLE 82. UNITED STATES MIGRAINE DRUGS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 83. UNITED STATES MIGRAINE DRUGS MARKET: LICENSE & PRICING

Companies Mentioned

  • Aegis Therapeutics
  • Alder Biopharmaceuticals
  • Allergan
  • Eli Lilly
  • GlaxoSmithKline
  • Impax Laboratories
  • Johnson & Johnson
  • Luitpold Pharmaceuticals
  • Pfizer
  • TG Therapeutics
  • Winston Pharmaceuticals

Methodology

Loading
LOADING...